To order this detailed 320+ page report, please visit this
A detailed review of
the current landscape of companies offering contract manufacturing services for
biologics, using microbial expression systems, along with information on their
year of establishment, company size, location of headquarters, number and location
of their production facilities, scale of operation (preclinical, clinical and
commercial), type of biologic(s) manufactured (peptides / proteins, antibodies,
vaccines, biosimilars, oligonucleotides, plasmid DNA and others), type of
microbial expression system(s) used (bacterial, yeast and others), type of
fermenter(s) employed (single-use fermenters, stainless steel fermenters and
others), type of manufacturing service(s) offered (cell banking, process
development and characterization, analytical method development and testing,
quality assurance and control, scale-up, downstream processing and regulatory
support), and regulatory accreditations / certifications received (if any).
company competitiveness analysis, highlighting key players engaged in microbial
based contract manufacturing based on their experience (considering the year of
establishment of the firm) and expertise (taking into account their service
portfolio, number of different types of biologics manufactured and number of distinct
expression system(s) used).
An analysis of the
various partnerships signed within this domain, with a focus on microbial
contract biomanufacturing, since 2016, based on several relevant parameters,
such as year of partnership, type of partnership model adopted, scale of
operation, type of biologic, focus area, therapeutic area, most active players
(in terms of number of partnerships signed), and geography. Further, it
features a detailed analysis of the various mergers and acquisitions that were
carried out in this domain, highlighting the trend in terms of number of
players acquired between 2016-2020 (till May), along with the geographical
distribution of this activity.
An elaborate analysis
of the various expansion initiatives undertaken by contract manufacturers using
microbial expression systems in order to augment their capabilities, over the
period 2016-2020 (till May), taking into consideration several relevant
parameters, such as year of expansion, type of expansion (capability expansion,
capacity expansion, facility expansion and new facility), scale of operation of
manufacturing facility, type of biologic and location of manufacturing
A review of the
varied microbial based manufacturing initiatives undertaken by big pharma
players (shortlisted from the top 20 pharmaceutical companies as of 2019),
highlighting trends across various parameters, such as number of initiatives,
year of initiative and type of initiative.
proprietary 2×2 representation that was developed to assess the current market
scenario (in terms of existing competition and growth opportunities) across
emerging and established market segments.
Elaborate profiles of
key players that offer contract biomanufacturing services using microbial
expression systems across different geographies, namely North America, Europe
and Asia Pacific. Each profile features a brief overview of the company,
information related to its service portfolio, manufacturing capabilities and
facilities, recent developments and an informed future outlook.
A discussion on
industry affiliated trends, key drivers and challenges, under a SWOT framework,
which are likely to impact the evolution of this field. It also includes a
Harvey ball analysis, highlighting the relative impact of each SWOT parameter
on industry dynamics.
A case study
comparing the key characteristics of large molecule and small molecule drugs,
along with details on the various steps involved in their respective
discussion on the impact of COVID-19 outbreak on the overall microbial contract
biomanufacturing market, and the key initiatives undertaken by CMOs to combat
the challenges posed due to ongoing situation.
The report also features the likely
distribution of the current and forecasted opportunity across important market
segments, mentioned below:
Type of Product
(plasmid DNA, probiotics, microbiome-based biologics)
Type of Microbial Expression System
(Algae and fungi)
of End User
/ Very Large Companies
East and North Africa
To request sample pages, please visit this -
Key Questions Answered
are the leading CMOs with expertise in production of microbial biologics?
What are the preferred microbial expression systems used in
biologic development and manufacturing?
What are the key microbial fermentation technology
Who could be the potential partners for the microbial CMOs?
What kind of partnership models are commonly adopted by
stakeholders engaged in this domain?
What type of expansion initiatives are being carried out by
CMOs in this domain?
What initiatives are being undertaken by big pharma players
in this domain?
What are the key factors influencing the make (manufacture
in-house) versus buy (outsource) decision related to microbial fermentation?
What are the key trends within the microbial contract
How is the current and future market opportunity likely to be
distributed across key market segments?
You may also be interested in the following
Service Providers Market, 2020 – 2030
Discovery Services and Platforms Market (3rd Edition), 2020-2030
Biotherapeutic Products and Microbiome Contract Manufacturing Market: Focus on Active Pharmaceutical
Ingredients and Finished Dosage Forms, 2020 - 2030
(415) 800 3415